Back

Lundbeck revives $448 million AprilBio drug for neurological diseases

Verifying
  • Lundbeck resumed APB-A1 development and shifted Lu AG22515 toward neuroimmunological diseases.
  • 2021 agreement values the program at up to $448 million, including upfront and milestone payments.
  • AprilBio's APB-R3 is scheduled to release full Phase 2a results in late September.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.